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Optimal management of severe aortoiliac occlu-
sive disease is complex because of the development
of multiple competing therapeutic options. In many
medical centers, traditional direct and indirect vas-
cular reconstructive procedures are superseded by
non-operative catheter-based endoluminal therapies,
such as percutaneous transluminal angioplasty
(PTLA) and stent deployment. Compelling data
from advocates of various in-flow options can be
found simultaneously to support direct surgical,
indirect surgical, and non-operative endovascular
treatment strategies. However, differences in how
results of these alternative methods are collected,
analyzed, compared, and subsequently reported
contribute to confusion as to which option is best.
Accumulated data on the treatment of aortoiliac
occlusive disease has concentrated on mortality, tech-
nical success of operative and non-operative proce-
dures, long-term patency, and immediate complica-
Aortoiliac stent deployment versus surgical
reconstruction: Analysis of outcome 
and cost
Jeffrey L. Ballard, MD, FACS, John J. Bergan, MD, FACS, Pramil Singh,
MPH, Holly Yonemoto, MBA, and J. David Killeen, MD, FACS, Loma Linda,
Calif.
Purpose: The purpose of this study is to compare complication rate, primary patency, and
cost of stent deployment with direct surgical reconstruction for the treatment of severe
aortoiliac occlusive disease.
Methods: From March 1, 1992, to May 31, 1996, 119 patients receiving treatment for
aortoiliac occlusive disease were analyzed after exclusions. Sixty-five patients had stent
deployment and 54 patients had surgical reconstruction. Data were evaluated within and
between the groups by univariate and multivariate logistic regression, life-table, t-test,
and cross tabulation with c 2 analysis.
Results: There was no significant difference between the groups with regard to demo-
graphic features or presenting symptoms (all p values > 0.07). Incidence of procedure-
related complications was similar (p = 0.30). However, there were more systemic com-
plications in the surgery group (15 versus 2; RR = 5.5, p < 0.01) and more vascular
complications in the stent group (16 versus 3; RR = 12, p < 0.002). Incidence and type
of late complications were not appreciably different (all p values > 0.05). Cumulative
primary patency rate of bypass grafts was significantly better than stented iliac arteries
at 18 months (93% versus 77%), 30 months (93% versus 68%) and 42 months (93% ver-
sus 68%); p = 0.002, log rank. Multivariate analysis identified female gender (RR = 4.6,
p = 0.03), ipsilateral SFA occlusion (RR = 5.6, p = 0.01), procedure-related vascular
complication (RR = 9.7, p = 0.002), and hypercholesterolemia (RR = 5.0, p = 0.02) as
independent predictors of bypass graft or stent thrombosis. Mean total hospital cost per
limb treated did not differ significantly between surgery and stent deployment groups
($9383 versus $8626, respectively; p = 0.66, t-test).
Conclusions: Treatment of severe aortoiliac occlusive disease by surgical reconstruction or
stent deployment has a similar complication rate. Mean hospital cost per limb treated is
essentially equal. However, cumulative primary patency rate of bypass grafts is superior
to stents. Therefore, considering the elements of cost and patency, surgical revascular-
ization has greater value. The benchmark for cost-effective treatment of severe aortoili-
ac occlusive disease is direct surgical reconstruction. (J Vasc Surg 1998;28:94-103.)
Division of Vascular Surgery, School of Public Health,
Accounting Department, Loma Linda University Medical
Center
Presented at the Twelfth Annual Western Vascular Society
Meeting, Lana’i, Hawaii, Sep. 27–Oct. 1, 1997.
Reprint requests: Jeffrey L. Ballard, MD, FACS, Division of
Vascular Surgery, Loma Linda University Medical Center,
11175 Campus Street, Room #21123, Loma Linda, CA 92354
Copyright © 1998 by The Society for Vascular Surgery and
International Society for Cardiovascular Surgery, North
American Chapter.
0741-5214/98/$5.00 + 0 24/6/88975
JOURNAL OF VASCULAR SURGERY
Volume 28, Number 1 Ballard et al. 95
tions all without a cost comparison.1-33 These data
demonstrate the durability of direct and non-direct
surgical reconstructive techniques.30-33 They also
suggest that PTLA with or without stent deployment
is safe and effective treatment for atherosclerotic dis-
ease of the iliac arteries.1-20 Endovascular procedure-
related failures and complications range from 6.8% to
23.7%, and these rates are similar to those of more
traditional treatment options.2-33 Many authors have
demonstrated clinical improvement and early angio-
plastied and stented iliac artery primary patency rates
that challenge those of conventional surgical recon-
structive procedures. However, more sobering long-
term patency rates are now emerging.21-23 Clearly,
each treatment option for definitive correction of in-
flow abnormalities has inherent advantages and dis-
advantages. Therefore, controversy remains in this
area of contemporary clinical vascular surgery.
It is within this framework that we choose to
analyze a series of patients who were candidates for
either aortoiliac stent deployment or direct surgical
reconstruction over a 50-month period at Loma
Linda University Medical Center. Complication,
mortality, and cumulative primary patency rates
were compared according to guidelines accepted by
the Joint Council of the American Vascular
Societies.34 Also, actual hospital cost of each proce-
dure per limb treated was calculated for comparison.
PATIENTS AND METHODS
This consecutive, non-randomized patient series
compares direct surgical reconstruction with stent
deployment for the treatment of severe aortoiliac
occlusive disease. Therefore, all patients were con-
sidered to be operative candidates. No patient had
an associated aortoiliac aneurysm or was a prohibi-
tive medical risk. Decision for treatment was based
upon joint consultation between vascular surgeons
and interventional radiology staff. Patients were
excluded from analysis if a category 1 aortoiliac
lesion was treated by stent deployment because these
were not considered to be surgical lesions.35 Patients
with extraanatomic bypass grafts were also excluded
from analysis as these were not direct aortic recon-
structions.
These exclusions were applied to the 184 patients
who received treatment for severe aortoiliac occlusive
disease at Loma Linda University Medical Center
from March 1, 1992, to May 31, 1996. Out of this
group, 65 surgically fit patients (79 symptomatic
limbs) with category 2, 3, or 4 iliac artery lesions had
stent deployment and 54 patients (103 symptomatic
limbs) had surgical reconstruction.35 Sixty-five
patients were not analyzed for the following reasons:
a category 1 lesion was treated (37 patients), the
patient was considered to be a prohibitive surgical
risk (8 patients), or an extraanatomic bypass graft had
been placed (20 patients). Demographic data are list-
ed in Table I and pattern of aortoiliac and infrain-
guinal occlusive disease are listed in Table II.
Stents were deployed in the interventional radi-
ology suite as previously described.4,21 A Palmaz
stent was generally chosen if the lesion was focal and
the iliac artery was not tortuous or if the needle
puncture site was ipsilateral to the treated lesion. A
Wallstent was generally chosen for longer lesions,
particularly near the inguinal ligament, for the treat-
ment of tortuous iliac arteries and for contralateral
approaches to the treated lesion. A combination of
the two stents was generally used to provide extra
length when a Wallstent did not completely cover
Table I. Patient Demographics (N = 119)
Stent Group Surgery Group p
Mean Age 67 64 0.15
Sex 0.07
Male 65% 48%
Female 35% 52%
Incidence of
Coronary artery disease 63% 54% 0.30
Diabetes 27% 22% 0.40
Hypertension 72% 65% 0.38
Hypercholesterolemia 42% 41% 0.93
Smoking history 0.13
Past 34% 44%
Present 49% 50%
Presenting symptom 0.71
Disabling claudication 62% 65%
Limb threatening ischemia 38% 35%
Table II. Pattern of aortoiliac and infrainguinal
occusive disease (N = 182)
Stent Group Surgery Group p
Category of treated lesion
2 30% 0% 0.00
3 38% 37% 0.88
4 32% 63% 0.00
Iliac artery involvement
Common or external 66% 33% 0.00
Common and external 34% 67% 0.00
Superficial femoral artery
Patent/bypassed 56% 70% 0.09
Stenotic 14% 11% 0.51
Occluded 30% 19% 0.05
Tibial artery runoff
3 Vessel 38% 54% 0.03
2 Vessel 32% 38% 0.38
1 Vessel 30% 8% 0.00
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the treated lesion. Most patients (87%) in the surgi-
cal group had bilateral symptomatic disease.
Therefore, either aortobifemoral bypass (76%) or
aortobiiliac bypass (11%) was employed to recon-
struct in-flow. Ilio-femoral bypass (3), aorto-iliac
bypass (2), aorto-femoral bypass (1), and ilio-pro-
funda bypass (1) were used in the rest of patients
(13%) with unilateral symptoms. Endarterectomy at
the femoral artery level accompanied the bypass pro-
cedure in 32% of patients. Polytetrafluoroethylene
(Goretex, W.L. Gore & Assoc., Flagstaff, Ariz.)
grafts were used more frequently than polyethylene
terephthalate (Hemashield, Boston Scientific,
Oakland, N.J.) (Dacron) grafts (81% versus 19%) in
this series.
Follow-up data were available for all patients,
and patients were examined clinically before and
after each procedure by the vascular surgery service.
Thereafter, patients were examined at 2- or 3-month
intervals in the vascular surgery clinic. Graft patency
and iliac artery stent patency were assessed directly
by arteriography in 49 (27%) limbs or indirectly by
clinical criteria in 133 (73%) limbs at latest follow-
up.36 Clinical criteria primarily included palpation of
a femoral or graft pulse distal to the treated iliac
artery and maintenance of achieved improvement in
the post-procedure ankle brachial index (ABI). Cost
(not charge) data were obtained directly from our
accounting office. This included all direct costs
related to the surgical or interventional radiologic
procedure in addition to indirect costs of overhead
that were allocated to the treating department.
Direct costs, some of which were based on an hourly
rate, included all labor and supplies related to deliv-
ery of the procedure. Indirect costs included expens-
es of cost centers that were administrative or ancil-
lary in nature, as well as expenses such as utilities
that were allocated on a basis such as square footage
of the providing department. Professional fees were
based on current Medicare reimbursement in our
region for surgical reconstruction or stent deploy-
ment. All other data were obtained retrospectively
through review of hospital records and out-patient
clinic charts.
Group comparison and means testing was by t-
test and cross tabulation with c 2 analysis. Univariate
analysis was used to identify risk factors significant
for bypass graft or stent thrombosis. Multivariate
logistic regression analysis was then performed using
the variables found to be significant in univariate
analysis to determine factors that independently pre-
dicted bypass graft or stent thrombosis. Cumulative
primary patency and survival rates were determined
by life-table analysis. Statistical significance was
assumed if the p value was less than 0.05.
RESULTS
There was no significant difference between the
groups with regard to demographic features or pre-
senting symptoms (all p values > 0.07) as shown in
Table I. However, the pattern of aortoiliac occlusive
disease was decidedly different between the groups
as demonstrated in Table II. In the surgery group,
there were significantly more category 4 lesions
treated, and more often the atherosclerotic disease
involved the common and external iliac arteries.
Superficial femoral artery (SFA) patency status ipsi-
lateral to the treated iliac artery was similar for both
groups although the difference in incidence of SFA
occlusion almost reached statistical significance (p =
0.05). In addition, more patients in the stent group
had single vessel tibial artery runoff (p = 0.00), and
more patients in the surgery group had three-vessel
tibial artery runoff (p = 0.03).
Incidence of procedure-related complications
was similar (p = 0.30) between the groups.
However, more systemic complications occurred in
the surgery group (15 versus 2; RR = 5.5, p < 0.01),
and more vascular complications were experienced
in the stent group (16 versus 3; RR = 12, p < 0.002).
Systemic complications associated with surgery that
required specific treatment included pneumonia (3),
cardiac dysrhythmias (2), cholecystitis (2), perioper-
ative stroke (1), nonspecific colitis (1), ileus (1), uri-
nary retention (1), myocardial infarction (1), diver-
ticulitis (1), acute renal insufficiency (1), and urinary
tract infection (1). In the stent group, systemic com-
plications were limited to two retroperitoneal
hematomas that required hospital admission and
transfusion of packed red blood cells. Vascular com-
plications in the surgery group requiring treatment
included acute occlusion of an aortobifemoral
bypass graft (1), SFA dissection (1), and thrombosis
of a previously placed femoral-popliteal artery bypass
graft (1). In the stent group, vascular complications
requiring adjunctive treatment included hemody-
namically significant iliac artery dissection (8), acute
iliac artery thrombosis (5), distal embolization (2),
and stent infection (1). Incidence and type of late
complications (> 30 days) were not appreciably dif-
ferent between the groups (all p values > 0.05).
Mean patient follow-up was 22 months (range 1
to 67 months). Early hemodynamic improvement,
as evidenced by a significant change in ankle brachial
index of the treated extremity was noted following
either procedure (mean increase, -0.40 mm Hg, p =
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0, paired t-test). Clinical improvement, as evidenced
by no symptoms and a palpable graft or femoral
pulse distal to the treated iliac artery was noted in
162 of 182 (89%) limbs at latest follow-up. Six limbs
(3%) were clinically unchanged, two (1%) were
worse, and five (3%) had undergone major lower
extremity amputation at latest follow-up. Patient
deaths account for seven (4%) other limbs. There
was one (1.9%) perioperative death from myocardial
infarction and cardiac failure in the surgery group
and no periprocedure deaths in the stent deploy-
ment group. Deaths were also noted in two (3.7%)
other patients in the surgery group and three (4.6%)
patients in the stent group at the time of follow-up.
These mortalities were a result of myocardial infarc-
tion (2), respiratory failure (1), and metastatic can-
cer (2). Cumulative patient survival was not signifi-
cantly different between the two groups (p = 0.97,
log rank analysis) as demonstrated in Figure 1.
However, cumulative primary patency rate of bypass
grafts was significantly better than stented iliac arter-
ies at 18 months (93% versus 77%), 30 months (93%
versus 68%), and 42 months (93% versus 68%); p =
0.002, log rank analysis (Figure 2).
Risk factors identified by univariate analysis to be
significant predictors of bypass graft or stent throm-
bosis included stent deployment (RR = 3.7, p =
0.03), female gender (RR = 5.0, p = 0.005), ipsilat-
eral SFA occlusion (RR 3.8, p = 0.01), procedure-
related vascular complication (RR = 6.3, p = 0.002),
and hypercholesterolemia (RR = 4.1, p = 0.01).
Other risk factors had no predictive value (coronary
artery disease, hypertension, diabetes, age, smoking
history, tibial artery runoff, and location of iliac
artery lesion). Multivariate logistic regression analy-
sis identified procedure-related vascular complica-
tion (RR = 9.7, p = 0.002), ipsilateral SFA occlusion
(RR = 5.6, p = 0.01), female gender (RR = 4.6, p =
0.03), and hypercholesterolemia (RR = 5.0, p =
0.02) as independent predictors of bypass graft or
stent thrombosis (Table III).
Within the stent group, there was a significant
linear relationship between category of treated iliac
artery and ultimate risk of stented iliac artery throm-
bosis (p = 0.01). Similarly, cumulative primary paten-
cy of stented iliac artery occlusions was worse than
stented iliac artery stenoses (p = 0.0004, log rank).
Stented iliac artery cumulative primary patency was
not influenced by location of treatment within the
iliac artery (that is, common versus external iliac
artery), p = 0.87; log rank. Cumulative primary
patency of bypass grafts was not influenced by type of
reconstruction (that is, aortobifemoral versus aorto-
biiliac versus unilateral configurations) nor by
whether femoral endarterectomy accompanied the
procedure (p = 0.68 and 0.10, respectively; log rank).
Excluding professional fees, mean total hospital
cost per limb treated did not differ significantly
between surgery and stent deployment groups
($9383 versus $8626, respectively; p = 0.66, t-test)
(see Table IV). Total cost per limb treated for the
surgery group ranged from $3223 to $35,531, and
for the stent group the range was from $1357 to
$70,312. The highest percentage of total hospital
cost was related to direct procedure costs. Mean
direct cost for surgical reconstruction was $6196
(range, $1950 to $25,270) and for stent deploy-
Table III. Predictors of bypass graft or stent
thrombosis
Relative Risk p
Univariate
Stent deployment 3.7 0.03
Female gender 5.0 0.005
SFA occlusion 3.8 0.01
Vascular complication 6.3 0.002
Hypercholesterolemia 4.1 0.01
Multivariate
Female gender 4.6 0.03
SFA occlusion 5.6 0.01
Vascular complication 9.7 0.002
Hypercholesterolemia 5.0 0.02
Fig. 1. Life-table analysis of cumulative patient survival
stratified for surgical reconstruction and stent deployment
groups. Standard error < 10% for both plots through 42
months.
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ment was $5524 (range, $743 to $48,110); p =
0.88, t-test. Even with inclusion of professional fees
based on current Medicare reimbursement in our
region, mean total hospital cost between the two
groups was essentially the same per limb treated
($10,585 for surgical reconstruction versus $9161
for stent deployment; p = 0.24, t-test). This cost
similarity was noted despite a significant difference
in mean length of hospital stay between the two
groups (10 days for surgery versus 2 days for stent
deployment; p = 0.02, t-test).
DISCUSSION
In this era of technologic revolution we have, for
the first time, directly compared surgical vascular
reconstruction to endovascular reconstruction for
the treatment of severe aortoiliac occlusive disease.
Despite the non-randomized nature of this patient
series, a number of observations made in this expe-
rience help to clarify these seemingly competitive
therapies. Group differences in cumulative primary
patency, type of complication, and cost are high-
lighted in this retrospective review.
As previously noted, there is a significant linear
relationship between category of iliac artery treated
and ultimate risk of stented iliac artery thrombosis
(p = 0.01).21,22 The more severe the lesion, the
greater the likelihood of thrombosis and decreased
long-term patency after stent deployment.
Additionally, stented iliac artery occlusions had
decreased cumulative primary patency compared to
stented iliac artery stenoses. Therefore, cumulative
primary patency rates might be expected to be simi-
lar in this experience or better for stents because
more category 2 lesions were treated by stent
deployment and more category 4 lesions were treat-
ed by surgical reconstruction. However, this was not
the case despite the apparent prejudice against
surgery. Cumulative primary patency rate of stented
iliac arteries was decidedly inferior to surgical recon-
struction at 18, 30, and 42 months by life-table
analysis.
Table IV. Cost comparison per limb treated
Stent group Surgery group p
Total mean hospital cost $9161 $10,585 0.24
including professional fee
Total mean hospital cost $8626 $9383 0.66
excluding professional fee
Mean direct procedure cost $5524 $6196 0.88
Fig. 2. Life-table analysis of cumulative primary patency stratified for surgical reconstruction
and stent deployment groups. Standard error < 10% for both plots through 42 months.
This difference in cumulative primary patency
was not influenced by group demographics or pre-
senting symptom and likely not affected by the
group variance in pattern of infrainguinal atheroscle-
rotic disease. More category 3 and 4 lesions were
treated by surgical reconstruction, and although
there was a significant difference in tibial artery
runoff, this variable was not found to influence graft
or stent patency by univariate analysis. The differ-
ence in incidence of SFA occlusion did approach sta-
tistical significance although, in general, the status of
the ipsilateral SFA was similar for both groups. This
variable was found to be an independent predictor of
graft or stent thrombosis. Compromised infrain-
guinal runoff has been noted to have an adverse
affect on long-term aortofemoral bypass graft paten-
cy, as well as on stented iliac artery paten-
cy.12,13,18,19,21,22,31-33 Femoral endarterectomy with
profundoplasty, a surgical adjunct, has been shown
to be important for prolonged aortofemoral graft
patency.31-33 In this experience, more thrombosed
graft limbs were noted in procedures without
femoral endarterectomy (6 to 0); however, this dif-
ference did not reach statistical significance (p =
0.10, log rank).
Cumulative primary patency rate of both bypass
grafts and stents was negatively influenced by female
gender, incidence of hypercholesterolemia, and inci-
dence of a procedure-related vascular complication.
Separate reports by Sapoval et al.18 and Laborde et
al.19 also recognize the negative influence of the
female gender on long-term angiographic and clini-
cal success of iliac artery stent deployment.
However, the significant difference in cumulative
primary patency cannot be attributed to difference
in gender or incidence of hypercholesterolemia
because these variables were not dissimilar between
the two groups. Remote manipulation of diseased
arteries most likely explains the higher rate of vascu-
lar complications in the stent deployment group.
This procedure-related variable certainly affected
stented iliac artery cumulative primary patency.
Despite this, in our opinion, the marked difference
in cumulative primary patency rate between the
groups is more related to the fact that during surgi-
cal reconstruction the lesion is bypassed completely
whereas during stent deployment the lesion is mod-
ified but not removed.
This fundamental contrast in the way the arterial
lesions were manipulated during each procedure
helps to explain why there was a difference in type of
complication between the two groups. Overall inci-
dence of procedure-related and late complications
was similar (all p values > 0.05). However, there were
more systemic complications in the surgery group
(15 versus 2; RR = 5.5, p < 0.01) and more vascular
complications in the stent group (16 versus 3; RR =
12, p < 0.002). General anesthesia, incisional pain,
and manipulation of the abdominal contents all con-
tributed to the perioperative problems associated
with the major open vascular surgery described in
this experience. However, the ability to have graft
origin and destination well beyond the arterial lesion
of interest without having to directly manipulate it
was borne out by the paucity of vascular complica-
tions that occurred during surgical reconstruction.
On the other hand, absence of general anesthesia,
peritoneal shock, and incisional pain explained the
very few systemic complications associated with the
endovascular procedures. This improved the ability
to streamline patient care and decrease hospital stay.
Multiple logistic regression analysis demonstrat-
ed that vascular complications in the stent deploy-
ment group were more common if there was pedal
gangrene (RR = 8.6, p = 0.02), if more than one
stent was deployed during the procedure (RR =
4.92, p = 0.05), or if the treated patient was female
(RR = 2.51, p = 0.06). The risk of a vascular com-
plication increased twofold if a female patient also
had ipsilateral SFA occlusion (RR = 4.92, p = 0.03).
Laborde et al.,19 reporting on a large series of
patients that had placement of an iliac artery stent,
noted that the female gender was predictive of a
higher periprocedure complication rate compared to
the male gender. Additionally, this risk for women
increased significantly if the pattern of iliac occlusive
disease was severe. In our experience, this increased
incidence of vascular complications in women was
not just limited to stent deployment. The relative
risk of a procedure-related vascular complication was
increased three-fold (RR = 2.9, p = 0.01) for both
surgery and stent deployment groups if the patient
was female. Gagne et al.29 also noted that surgical
reconstruction was often complicated by intra-arter-
ial thromboembolic events in some women with
premature aortoiliac atherosclerosis. Small caliber
vessels in women may have contributed to the
observed increased risk for procedure-related vascu-
lar complications during either surgical reconstruc-
tion or stent deployment.
Despite a notable difference between the two
groups in length of hospital stay, mean total hospital
cost per limb treated did not differ significantly
between the surgical reconstruction and stent
deployment groups ($9383 versus $8626, respec-
tively; p = 0.66, t-test). Even with inclusion of pro-
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fessional fees based on current Medicare reimburse-
ment in our region, mean total hospital cost between
the two groups is essentially the same per limb treat-
ed ($10,585 for surgical reconstruction versus $9161
for stent deployment; p = 0.24, t-test). This is true
despite the fact that Medicare reimbursement for
aortoiliac reconstruction (CPT code #35641,
$1847) and for aortofemoral reconstruction (CPT
code #35646, $2052) is higher than the average pro-
fessional reimbursement for one iliac artery stent
deployment, which is approximately $978. However,
because of the convoluted way in which interven-
tional radiology procedures are billed, it is difficult at
best to derive accurate professional fee cost figures
for these endovascular procedures.
Cost per patient encounter in this experience was
higher for surgical reconstruction. However, the vast
majority of surgical patients (87%) had bilateral
reconstruction for bilateral symptomatic aortoiliac
occlusive disease, and most of the stent patients
(85%) had unilateral reconstruction for a unilateral
problem. No patient in this experience had a bilater-
al procedure for unilateral disease. In this regard, we
believe cost figures derived on a per limb basis are a
more accurate reflection of the true cost of treat-
ment for symptomatic aortoiliac occlusive disease.
This per-limb calculation becomes even more mean-
ingful when one considers cost and patency. For
essentially the same healthcare dollars spent per limb
treated, cumulative primary patency of bypass grafts
at 42 months was 93% compared to 68% for stented
iliac arteries over the same time interval. At present,
surgical reconstruction of iliac artery occlusive dis-
ease remains a durable, cost effective procedure.
This overall cost similarity per limb treated
between the two procedures is driven to a degree by
the high cost of new technology. Most of the equip-
ment used for a typical interventional radiologic 
procedure is not reusable, and stents are not inexpen-
sive. Self-expandable Wallstents (Schneider Inc.,
Minneapolis, Minn.) cost $995 to $1500, and bal-
loon-expandable Palmaz stents (Johnson & Johnson
Interventional Systems, Warren, N.J.) cost $600 to
$800, depending on the stent length. The perceived
cost savings of a Palmaz stent becomes a non-issue for
longer lesions that may require multiple Palmaz stents
versus one Wallstent. An unexpected procedure-relat-
ed complication that necessitates deployment of addi-
tional stents will increase procedure cost as will subse-
quent interventions following stented iliac artery
thrombosis. If adjunctive thrombolysis is required,
the cost of the procedure can be driven upward sub-
stantially. Mean actual drug cost for urokinase, which
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was used during nine procedures in this series, was
$333 (range $692 to $6228). In addition, the cost of
a stent procedure can increase substantially if a pro-
fessional fee is billed for predilation percutaneous bal-
loon angioplasty prior to stent deployment (not our
practice) or if additional balloon angioplasty is used to
further expand a deployed stent.
Cost of surgical reconstruction is driven by direct
costs associated with the operating room and increased
length of hospital stay. Type of graft did not signifi-
cantly contribute to a procedure cost differential either
within the surgical group or between the two groups.
In our hospital setting, the cost of a bifurcated PTFE
or polyethylene terephthalate (Dacron) graft is similar
to a Palmaz stent, and the cost difference between the
two grafts is only $79. Continued quality improve-
ment efforts made to eliminate waste in the operating
room, decrease in-patient hospital stay, and decrease
postoperative recovery time will help to contain cost in
the future. In our current practice, patients are admit-
ted the day of surgery for aortic reconstruction.
Postoperative time in an intensive care unit setting is
minimized, and early discharge (after 4 or 5 in-patient
days) is the expected norm. These measures aimed at
streamlining operative treatment have been well
received even though a significant number of patients
having aortic reconstruction are retired and not as
concerned about their length of stay as are hospital and
managed care administrators.
CONCLUSIONS
There is a similar complication rate for treatment
of severe aortoiliac occlusive disease by surgical
reconstruction or by stent deployment, although
there are more vascular complications associated
with stent deployment. Mean hospital cost per limb
treated is essentially equal. However, cumulative pri-
mary patency rate of bypass grafts is superior to
stents. The elements of cost and patency equate with
value. Therefore surgical revascularization has the
greater value. The gold standard for cost-effective
treatment of severe aortoiliac occlusive disease
remains direct surgical reconstruction.
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superiority of bypass grafting especially was pronounced
when the disease was most severe. Secondly, the financial
costs are equivalent in the operative and primary stent
groups. The data were presented on a per limb basis. Most
bypass grafts encompassed both limbs, whereas most pri-
mary stents treated only one. Consequently, I had diffi-
culty making an intuitive cost comparison between the
groups.
Notwithstanding, the presentation of data like these at
a surgical meeting is understandably an occasion for unre-
strained rejoicing. Rejoicing, yes; gloating, no. Dr. Ballard
has preached a gospel to the converted. I suspect, howev-
er, that the devil is hiding in the details.
First, did we mistakenly wander into the wrong meet-
ing? Should this be the SCVIR meeting? Of these severe-
ly afflicted patients, 55% were treated by an intervention-
al radiologist. Moreover, if all treated patients are includ-
ed, that number increases to 60%. We are unquestionably
the minority party in this therapeutic selection.
Second, if one investigated other outcomes, such as
time lost until return to work, or for that matter, return-
ing to work at all, which group—surgery or primary
stent—would come out on top? Like it or not, more
patients prefer an awake percutaneous procedure that
requires 2 to 3 inpatient hospital days as compared with a
long and painful hernia-prone incision with 2 to 3 days in
the intensive care unit.
Then again, there are stent-related technical questions
that I have chosen to leave to other discussants. Is it
appropriate that we should ask technical questions when
there are no interventional radiologists listed among the
authors even though they performed the transluminal
interventions? Most journals espouse the position that the
people who did the work should be included on the mast-
head of the paper—even if only among the trailing list of
“et al.’s” that confer authorship.
Then there is the tantalizing question: why are there
so many stents? In the preceding paper, 27% of the
patients received one or more stents, not the 100% that
the Loma Linda group deployed. Were these all primary
stents? In our series, presented by Dr. Bob Harris at these
meetings 7 years ago, our primary patency rate for aor-
toiliac balloon angioplasty in a similar group of patients
was 88% at 1 year. That report predated the availability of
stents. Your 1-year patency rate for stented patients was
75% versus our secondary patency rate of 92%. To my
mind, the obvious question is not whether we should be
using so many stents, but whether we can rely on inter-
ventional radiologists to decide who should receive a stent
and who should not?
The subject of stenting brings me inevitably to the
holy grail of contemporary medicine—or should I say
health caredelivery? What
are the real costs? I take reassurance from the presence
of the hospital accountants who are listed among the
authors, but I doubt that we could perform aortofemoral
bypass grafting for the approximately $10,000 that you list
in your paper. Do you feel sufficiently confident in that
number to offer it to insurance companies as a total price
carve-out or package price? I believe that Dr. Ballard has
come as close as anyone to date in solving the conundrum
of cost versus charges. I have no reason to doubt that his
data are not valid and correct.
However, consider the case of a single 294 Palmaz
stent. The company sells the stent to the hospital for
$800; that is cost. Next, the hospital sells it to the patient
for $1,600; that is charge. That difference may seem out-
rageous, and for hospitals that charge $2,500 or $3,000 or
more, it is, but there is some justification. There are costs
for stocking the item. Also, where will the money be to
pay for the hospital chaplain, the library, the operator, the
medical records, or the administration? These services are
hidden, together with profit and depreciation, in the cost
versus charges differential. My conclusions from reading
this paper are as follows. On a level playing field, surgery
is clearly superior to primary stent angioplasty. Read the
paper, and be of good heart, but do not overindulge in
self-congratulation. The devil is hiding in the details.
Dr. Jeffrey L. Ballard. At Loma Linda, I was told that
there were no devils. Maybe I had better rethink this.
Thank you, Dr. Andros. You mentioned a number of
thoughtful questions, and I will try to address as many as
I can. One of the issues that you mentioned was how soon
these patients can return to work. I agree that most
patients would prefer a simple outpatient procedure.
However, in this particular age group, most patients are
retired.
In our current practice, stents are deployed in the inter-
ventional radiology suite as an outpatient procedure.
Patients having direct surgical reconstruction are approached
from a left flank incision, and they are home within 3 to 
4 days.
Most of these patients did have one stent placed, and
they were not all necessarily placed primarily. There were
some placed after an unsuccessful angioplasty. These
details were discussed in a previously published manu-
script. So, I did not get involved with that in this particu-
lar paper.
The decision for treatment was always made in concert
with our interventional radiologists. So, none of these
procedures were unilateral decisions from either party,
which I think is an important point.
You mentioned cost. I agree with you that it is diffi-
cult to examine some of this data. However, the cost data
presented do include indirect costs from ancillary depart-
ments, such as accounting and housekeeping.
These cost figures are not perfect, but they are as close
as I can get to having something tangible for comparison.
Dr. Samuel Eric Wilson (Orange, Calif.). In deter-
mining the patency rate, which anatomical site was the
index lesion? For example, if the stent was placed on the
right side, but the untreated left iliac progressed to occlu-
sion, did you consider this a failure of stenting?
I think that the reintervention rate even for the con-
tralaterel lesion increases the cost of angioplasty and stent-
ing. It should be included in calculations of cost, and also,
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to be fair, we should include costs for management of late
complications of surgery. So, in fact, the cost of any vascu-
lar treatment may need to be calculated over 2 or 3 years.
I thought your costs seemed low, espeially because a
few years ago the Los Angeles Times reported that
Medicare considered your institution one of the most
costly in the state of California. Just over $10,000 for a
10-day hospital stay seems low.
Professional fees of over $1,000 would not seem to
include the anesthesia costs—which may be that much
alone—or consultant costs for management of systemic
complications. Perhaps you could just tell us in general
how you got reached numbers. Did these come from
patients’ bills, or were they reported to you as an average
from hospital statistics?
Finally, for most aortoiliac disease, we have lost the
battle with the interventionalists and the numbers speak
for themselves. In 1994, there were only 30,000 aortoili-
ac/aortofemoral bypass grafts performed in the United
States, and some of those were probably miscoded as
aneurysm procedures.
So I think most of this work has gone to the interven-
tionalists. We need this type of information to show that
perhaps it should stay in greater part with the surgeons.
Thank you.
Dr. Ballard. Thank you, Dr. Wilson. The patency rate
was calculated on the vessel that was treated. Cost data also
was calculated per limb treated. We do not have cost data
for 2 or 3 years because this was a hospital-based study.
Cost data came directly from our accounting depart-
ment and do include all of the consultants and other indi-
rect costs that were involved with either procedure.
Dr. Wesley S. Moore (Los Angeles, Calif.). I enjoyed
this paper. Would the authors clarify one issue concerning
their reporting of cost? If I understand your data correct-
ly, you reported cost on the basis of cost per limb rather
than cost per patient. This confuses me because we are
admitting patients to the hospital, not legs. In addition,
this method of calculation may tend to skew cost data in
favor of bypass graft rather than angioplasty. Because a sur-
geon is more likely to perform an aortobifemoral bypass
graft, total cost would be divided in half. On the other
hand, if there is an isolated iliac lesion, single angioplasty
would be performed, thus incurring the entire hospital
cost against angioplasty. So, if you take the extreme of
both cases, the actual hospital cost may have to be dou-
bled for surgery as compared with balloon angioplasty
because you are more likely to perform an aortobifemoral
bypass graft with surgery but perform a unilateral iliac
angioplasty with endovascular intervention. I would
appreciate if you would clarify this issue for me.
Dr. Ballard. This is one of the issues with which we
struggled. We decided to look at cost per limb treated
because some patients only had one limb treated and oth-
ers had both limbs treated. Although the atherosclerotic
disease process affects the entire aortoiliac system, it is not
our practice to put in bifurcated grafts if there is only sig-
nificant unilateral disease.
